BVT Discount Zert SDZ 22.04.2025/ DE000VD3JX79 /
6/27/2024 1:56:37 PM | Chg.-0.010 | Bid3:02:38 PM | Ask3:02:38 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
26.640EUR | -0.04% | 26.630 Bid Size: 7,600 |
26.690 Ask Size: 7,600 |
SANDOZ GROUP N | - CHF | 4/22/2025 | Call |
GlobeNewswire
5/22
Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilar...
GlobeNewswire
4/30
Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of San...
GlobeNewswire
4/30
Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab bios...
GlobeNewswire
4/22
Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immun...
GlobeNewswire
3/21
Sandoz opens new antibiotic production facility in Austria, to significantly increase capacity for l...
GlobeNewswire
3/4
Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leader...
GlobeNewswire
2/29
Sandoz US subsidiaries resolve generic drug antitrust class action litigation with direct purchaser ...
GlobeNewswire
1/31
Sandoz launches first and only biosimilar for multiple sclerosis, Tyruko® (natalizumab), in Germany
GlobeNewswire
1/22
Sandoz announces agreement to acquire CIMERLI® business from Coherus, strengthening position in US m...
GlobeNewswire
11/21/2023
Sandoz launches Hyrimoz® (adalimumab) high-concentration formulation in Europe, aiming to improve pa...